首页> 美国政府科技报告 >Antigen Markers for Clinical Manifestation and Prevention of HTLV-III/LAV Infection.
【24h】

Antigen Markers for Clinical Manifestation and Prevention of HTLV-III/LAV Infection.

机译:用于临床表现和预防HTLV-III / LaV感染的抗原标记物。

获取原文

摘要

During this year's research we have found that the vpr gene product of HIV 1 is localized in the virion and that the C terminal portion of the gene is critical for its expression. We also found that the vpr open reading frame of SIV encodes a virion-associated 11 kd protein. The protein reacts with sera from infected macaques and appears to be dispensable for virus replication. In work with HIV 1 gp 120 we found that antibodies that are cross-reactive for HIV 1 and HIV 2 gp 120 are correlated with better clinical outcome. In addition, we also located a potential CD4 binding domain on the N-terminal conserved region of HIV 1 gp 120, suggesting that binding may occur through discontinuous domains.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号